AKRO News and Press, Akero Therapeutics Inc.

2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...

SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...

2024-06-11 13:49:24 ET More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Seeking Alpha’s Quant Rating on Akero Therapeutics Historical earnings data for Akero Therapeutics Financial information for Akero Therapeutics Re...

2024-06-11 13:28:02 ET More on Madrigal Pharmaceuticals Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madriga...

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-10 21:15:01 ET Wolfe Research analyst issues OUTPERFORM recommendation for AKRO on June 10, 2024 07:16PM ET. AKRO was trading at $22.99 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy reco...

2024-06-10 21:00:04 ET Andy Chen from Wolfe Research issued a price target of $40.00 for AKRO on 2024-06-10 19:16:00. The adjusted price target was set to $40.00. At the time of the announcement, AKRO was trading at $22.99. The overall price target consensus is at $39.00...

2024-06-09 17:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations ...